hip fracture
Conditions
Interventions
Intervention Group:Following general anesthesia, transcutaneous electrical acupoint stimulation (TEAS) was administered at Hegu (LI4), Neiguan (PC6), Zusanli (ST36) and Sanyinjiao (SP6) until the end
control group:Following the induction of general anesthesia, transcutaneous electrical acupoint stimulation (TEAS) electrode pads were applied to the Hegu (LI4), Neiguan (PC6), Zusanli (ST36), and San
Sponsors
Shanghai Sixth People's Hospital
Eligibility
Sex/Gender
All
Age
60 Years to 74 Years
Inclusion criteria
Inclusion criteria: 1.Patients diagnosed with hip fracture without combined other fractures, scheduled for elective surgical treatment. 2.Aged from 60 to 74 years old. 3.American Society of Anesthesiologists (ASA) physical status classification ?–?. 4. Body Mass Index (BMI): 18.5~29.9 kg/m² 5.Preoperative ICFS-10 score = 24 points. 6.Voluntarily participate in this trial, with the informed consent form signed by the subject or their legal representative.
Exclusion criteria
Exclusion criteria: 1. Patients with NYHA functional class ?–?; those who have suffered acute myocardial infarction or unstable angina within 3 months; patients with malignant arrhythmias such as ventricular tachycardia and ventricular fibrillation; and those with cardiomegaly with a cardiothoracic ratio > 0.7. 2. Patients with very severe chronic obstructive pulmonary disease (FEV1.0 45 mmHg; those requiring long-term invasive/non-invasive ventilatory support; patients with severe interstitial lung disease and severe pulmonary hypertension. 3. Patients with chronic kidney disease (CKD) stage 4–5; uremia requiring hemodialysis or peritoneal dialysis replacement therapy; acute kidney injury (AKI) stage 3; those with serum creatinine exceeding 2 times the upper limit of normal accompanied by urine output < 0.5 ml/(kg·h) for more than 4 consecutive hours. 4. Patients with multiple organ dysfunction syndrome (MODS), multiple organ failure (MOF), or severe hypothyroidism. 5. Long-term users of anticonvulsants, antidepressants or other psychotropic drugs. 6. Patients with preoperative hearing, speech or cognitive disorders who cannot achieve effective communication. 7. Patients with severe preoperative sinus bradycardia, sick sinus syndrome, second-degree type ? and above atrioventricular block, or those implanted with a cardiac pacemaker. 8. Those with local skin allergy, damage or infection at the intended stimulation site. 9. Participants enrolled in other clinical trials within the past three months. 10. Patients with previous treatment history of percutaneous transcutaneous electrical acupoint stimulation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of early postoperative fatigue; | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum interleukin-1ß;High-sensitivity C-reactive protein (hs-CRP);Serum interleukin-6;Neutrophil-to-Lymphocyte Ratio;Postoperative sleep quality score; | — |
Countries
China
Contacts
Public ContactCheng Chen/Zhang NanNan
Shanghai Sixth People's Hospital
Outcome results
None listed